LightNews — News, ranked by scholars

EuroPCR 26: VESALIUS-CV: Evolocumab in Stented Patients Without Prior MI

July 28, 2026 at 7:03 AM

Ordo Fraterna Fibonacci

@ordofibonacci.bsky.social

EuroPCR 26: VESALIUS-CV: Evolocumab in Stented Patients Without Prior MI
Radcliffe Cardiology
youtu.be/pLDVKpINAPQ?...

EuroPCR 26: SMART Trial: Three-Year Outcomes in Small Aortic Annulus TAVR

July 28, 2026 at 7:03 AM

Ordo Fraterna Fibonacci

@ordofibonacci.bsky.social

EuroPCR 26: SMART Trial: Three-Year Outcomes in Small Aortic Annulus TAVR
Radcliffe Cardiology
youtu.be/pljQXP5OQwo?...

EuroPCR 26: Valve-in-Valve TAVR with Navitor: 30-Day Outcomes in Failed Surgical Bioprostheses

July 14, 2026 at 7:13 AM

Ordo Fraterna Fibonacci

@ordofibonacci.bsky.social

EuroPCR 26: Valve-in-Valve TAVR with Navitor: 30-Day Outcomes in Failed Surgical Bioprostheses
Radcliffe Cardiology
youtu.be/GGNtH8BHbc8?...

NVM Cardiology Meeting Reflections: EuroPCR 26 Wrap Up with Prof Van Mieghem

July 14, 2026 at 7:12 AM

TCTMD

@tctmd.bsky.social

Does the use of AI in academic cardiology help or hinder researchers? On this episode of On Record, @yaelmaxwell.bsky.social sits down with Thomas Modine and Louis-Marie Desroche at #EuroPCR 2026 to discuss the benefits and potential pitfalls. www.tctmd.com/videos/on-re...

July 7, 2026 at 6:11 PM

TCTMD

@tctmd.bsky.social

On this episode of On Record, @yaelmaxwell.bsky.social speaks with Michiel Voskuil and Roberto Scarsini to discuss the data they presented at #EuroPCR 2026 about when PCI should be performed in relation to TAVI. www.tctmd.com/videos/on-re...

July 2, 2026 at 7:06 PM

Ordo Fraterna Fibonacci

@ordofibonacci.bsky.social

NVM Cardiology Meeting Reflections: EuroPCR 26 Wrap Up with Prof Van Mieghem
Radcliffe Cardiology
youtu.be/Tju-SkIsjRM?...

Nyra Medical Wins Jon DeHaan Foundation Award for Cardiology Innovation During EuroPCR 2026

June 19, 2026 at 6:30 AM

Thiard News@F4F

@newsen.bsky.social

Nyra Medical Wins Jon DeHaan Foundation Award for Cardiology Innovation During EuroPCR 2026#Paris #France #Cardiology #Nyra_Medical #CARLEN

At EuroPCR 2026, Nyra Medical was awarded the Jon DeHaan Foundation Award, honoring its innovative CARLEN technology for treating mitral valve issues.

third-news.com

June 18, 2026 at 3:57 PM

L2P Research

@l2plabs.bsky.social

Nyra Medical Receives Prestigious Jon DeHaan Foundation Award for Innovation in Cardiology at EuroPCR 2026

ATLANTA, June 18, 2026 /PRNewswire/ -- Nyra Medical, a leading innovator in structural heart therapies, today announced that it has been selected as the recipient of the 2026 Jon DeHaan Foundation Award for Cardiovascular Innovation, presented during EuroPCR 2026, the world's leading...

dlvr.it

June 18, 2026 at 2:09 PM

The Event MC

@eventmcuk.bsky.social

Check out this LinkedIn #promo for the #Philips experience I hosted at #EuroPCR2026 in #Paris in May - and well done to the whole #Blondefish team for a huge success.

www.linkedin.com/posts/blonde...

#EventMC #MC #MCing #Host #Hosting #Presenter #Presenting #InteractiveExperiences

#europcr2026 #philips #blondefish #experiencedesign | Blondefish

For EuroPCR 2026, we invited visitors inside the mind of the clinician... 💡 Guests followed colour-coordinated illuminated pathways through the space, leading them to expert stations and interactiv...

www.linkedin.com

June 17, 2026 at 11:52 AM

StockTitan

@stocktitan.net

#TFX Four‑Year BIOMAG™-I Study Results Presented at EuroPCR Confirm Long‑Term Safety and Sustained Performance of the Freesolve™ Resorbable Magnesium Scaffold (DREAMS 3G)

https://www.stocktitan.net/news/TFX/four-year-biomagtm-i-study-results-presented-at-euro-pcr-confirm-780gb45k34q1.html

Four‑Year BIOMAG™-I Study Results Presented at EuroPCR Confirm Long‑Term Safety and Sustained Performance of the Freesolve™ Resorbable Magnesium Scaffold (DREAMS 3G)

Teleflex (NYSE: TFX) reported four‑year BIOMAG™‑I data for the Freesolve™ Resorbable Magnesium Scaffold (DREAMS 3G), covering 116 patients at European centers.No cardiac death, target‑vessel myocardial infarction, or definite/probable scaffold thrombosis were seen through four years, and target lesion failure was 3.5%, supporting favorable long‑term safety and sustained performance.

www.stocktitan.net

June 9, 2026 at 10:30 AM

TCTMD

@tctmd.bsky.social

The novel transcatheter heart valve Myval for severe aortic stenosis has consistently demonstrated safety and efficacy comparable to contemporary balloon-expandable and self-expanding valves, based on 2-year data from the LANDMARK study. www.tctmd.com/news/landmar...
#EuroPCR 2026

LANDMARK: 2-Year Data Show Continued Safety and Efficacy of Unique TAVI Valve

Durability questions remain, but Myval appears comparable to contemporary devices on the market, says Patrick Serruys.

SELUTION De Novo Data Support ‘Keeping It Simple’ With DCB in Complex PCI

June 5, 2026 at 4:30 PM

TCTMD

@tctmd.bsky.social

For complex PCI, the Selution sirolimus-eluting balloon is considered safe and effective, making it an alternative strategy to systematic stenting, based on a subgroup analysis of the SELUTION De Novo trial. www.tctmd.com/news/selutio...
#EuroPCR 2026

The curves for TVF separated early and remained parallel in the complex cases, giving an advantage to the DCB group at 1 year.

TCTMD’s Top 10 Most Popular Stories for May 2026 cmacahilig@crf.org Mon, 06/01/2026 - 13:58 Caitlin E. Cox EuroPCR 2026 held center stage, with favorites also emerging from the annual Heart Rhythm and SCAI meetings.

June 3, 2026 at 5:26 PM

TCTMD

@tctmd.bsky.social

Conference season was in full swing during the month of May, and many of the top stories came from meetings like EuroPCR. TCTMD highlights the most popular articles of the month. www.tctmd.com/news/tctmds-...

June 2, 2026 at 3:32 PM

TCTMD

@tctmd.bsky.social

TCTMD’s Top 10 Most Popular Stories for May 2026

Unlocking Coronary Implant Impressive at 4 Years: BIOADAPTOR RCT

June 1, 2026 at 7:21 PM

TCTMD

@tctmd.bsky.social

The Bioadaptor coronary implant continues to outperform contemporary drug-eluting stent technology at four years of follow-up when used in patients with de novo lesions, according to results from the BIOADAPTOR RCT trial. www.tctmd.com/news/unlocki...
#EuroPCR 2026

The rate of target lesion failure with Bioadaptor was just 2.8%, which astounded many operators.

FFR-Guided PCI Reduces Revascularization Over a Decade, but Not Death

May 31, 2026 at 1:01 PM

TCTMD

@tctmd.bsky.social

Over a 10-year period, FFR-guided PCI reduces rates of revascularization but not death compared with optimal medical therapy, a distinction that emphasizes that it's not a survival treatment, based on new meta-analysis. www.tctmd.com/news/ffr-gui...
#EuroPCR 2026

A meta-analysis confirms what’s known: physiology-guided PCI is “not a survival treatment” when compared with OMT.

PCI Prior to TAVI of Only Modest Benefit in Patients With CAD and Aortic Stenosis

May 29, 2026 at 7:50 PM

TCTMD

@tctmd.bsky.social

Patients with coronary artery disease and aortic stenosis who are treated with PCI ahead of TAVI only see a small reduction in the risk of major adverse cardiovascular events, according to analysis from four randomized trials. www.tctmd.com/news/pci-pri...
#EuroPCR 2026

The totality of data suggests that routine PCI prior to TAVI is not warranted in the majority of cases, a meta-analysis shows.

After TAVI, Early Hemodynamic Valve Deterioration May Elude Detection

May 29, 2026 at 4:21 PM

TCTMD

@tctmd.bsky.social

Current criteria may not adequately detect early hemodynamic valve deterioration after TAVI, resulting in missed opportunities to prevent long-term clinical and valve-related issues, according to new data. www.tctmd.com/news/after-t...
#EuroPCR 2026

The problem is poorly captured by VARC-3 and gradient rises in the first 3 months have consequences, international data suggest.

Encouraging European Experience Seen With Transseptal TMVR

May 28, 2026 at 8:07 PM

TCTMD

@tctmd.bsky.social

Miss anything from the recent #EuroPCR 2026 conference that happened in Paris, France? TCTMD has got you covered! Visit the website to see all the exciting late-breaking studies and research that was presented at this year's meeting. www.tctmd.com/conference/e...

May 28, 2026 at 7:02 PM

TCTMD

@tctmd.bsky.social

Early use of TMVR with the Sapien M3 device shows promising procedural and clinical outcomes, based on new European data presented at #EuroPCR 2026. www.tctmd.com/news/encoura...

There are still some kinks to be ironed out, including risks of hemolysis and valve thrombosis, to put things on par with TEER.

Better Hemodynamics With Self-Expanding Valves in Small Annuli at 3 Years: SMART

May 28, 2026 at 4:07 PM

TCTMD

@tctmd.bsky.social

Using a self-expanding valve offers lower risk of bioprosthetic valve dysfunction and better hemodynamics for patients with severe symptomatic aortic stenosis and small annuli, according to new data from the SMART trial. www.tctmd.com/news/better-...
#EuroPCR 2026

Clinical event rates were still no different with longer follow-up, but one investigator thinks an advantage will emerge in time.

Consistent Benefit of LAA Closure Across Ages: CHAMPION-AF Subanalysis

May 27, 2026 at 6:58 PM

TCTMD

@tctmd.bsky.social

Patients with atrial fibrillation and higher risk of stroke who are eligible for long-term anticoagulation do better with left atrial appendage occlusion, regardless of their age, based on the results from the CHAMPION-AF trial. www.tctmd.com/news/consist...
#EuroPCR 2026

While the age-specific analysis was welcome, some felt it didn’t dig deep enough and others questioned the bleeding endpoints.